Chimeric Antigen Receptor T-cell therapies
GPTKB entity
Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
immunotherapy
|
| gptkbp:abbreviation |
gptkb:CAR-T_therapies
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:cellType |
T lymphocyte
|
| gptkbp:component |
transmembrane domain
antigen recognition domain costimulatory domain intracellular signaling domain |
| gptkbp:countryOfOrigin |
gptkb:China
gptkb:Europe gptkb:United_States |
| gptkbp:developedBy |
gptkb:Carl_June
gptkb:Michel_Sadelain |
| gptkbp:firstFDAApproval |
2017
|
| gptkbp:firstFDAApprovedProduct |
gptkb:Kymriah
gptkb:Yescarta |
| gptkbp:generation |
first generation
second generation third generation fourth generation |
| https://www.w3.org/2000/01/rdf-schema#label |
Chimeric Antigen Receptor T-cell therapies
|
| gptkbp:mechanismOfAction |
genetically engineered T cells express chimeric antigen receptors
|
| gptkbp:notableProduct |
gptkb:Carvykti
gptkb:Abecma gptkb:Tecartus gptkb:Kymriah gptkb:Yescarta gptkb:Breyanzi |
| gptkbp:processor |
cell expansion
leukapheresis lymphodepleting chemotherapy ex vivo genetic modification |
| gptkbp:regulates |
gptkb:FDA
gptkb:EMA |
| gptkbp:researchArea |
autoimmune diseases
solid tumors |
| gptkbp:riskFactor |
infection
B-cell aplasia hypogammaglobulinemia |
| gptkbp:sideEffect |
neurotoxicity
cytokine release syndrome |
| gptkbp:target |
tumor-associated antigens
|
| gptkbp:type |
personalized medicine
gene therapy |
| gptkbp:usedFor |
gptkb:cancer
multiple myeloma diffuse large B-cell lymphoma B-cell acute lymphoblastic leukemia |
| gptkbp:bfsParent |
gptkb:CAR-T_cell_therapies
|
| gptkbp:bfsLayer |
6
|